HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt

dc.contributor.authorAyman Yosry,
dc.contributor.authorAbdel-Bary, Akram
dc.contributor.authorHosny, Yaser Hatata Adel
dc.contributor.authorDoss, Wahid
dc.contributor.authorKamel, Sanna
dc.contributor.authorSaad, Yasmin
dc.contributor.authorOmran, Dalia
dc.contributor.authorOmar, Ashraf
dc.contributor.authorAl-Serafy, Magdy
dc.contributor.authorEsmat, Gamal
dc.contributor.authorSaid, Mohamed
dc.date.accessioned2026-04-08T07:25:17Z
dc.date.issued2012-04
dc.description.abstractObjectives: To analyze the effect of human leukocyte antigen tissue typing on outcome of live-donor liver transplant. Materials and Methods: Fifty recipients underwent live-donor liver transplant in the Dar Al-Fouad Hospital in Egypt and were retrospectively evaluated. Patients were classified into 2 groups: those with human leukocyte antigen +ve, and those with human leukocyte antigen -ve and donors. Hepatitis C virus-related end-stage liver disease was the main indication for transplant. Demographic data, preoperative laboratory data, results of human leukocyte antigen tissue typing, Child score, model for end-stage liver disease score, graft/recipient weight-ratio, ischemia times, surgical complications, postoperative laboratory data, liver biopsy, immunosuppression, and pulse steroids were collected. Graft and patient survivals were studied using Kaplan-Meier curves. Results: The mean model end-stage liver disease score was 18 ± 3.61 in group 1 and 17.73 ± 3.72 in group 2, with no significant difference. Graft/recipient weight ratio, ischemia times, and postoperative complications showed P = NS. Cyclosporine and tacrolimus were used in 5/9, 8/41, and 4/9 in group 1, and 32/41 in group 2 (P = NS). Rejection and pulse steroids were reported in 3/9 and 12/41 of group 1, and 3/12 and 11/41 of group 2 (P = NS). Hepatitis C virus-recurrence was diagnosed in 5/9 of patients (55%) and 8/41 of patients (29.5%) in groups 1 and 2 (P < .05). No statistical difference was found regarding mortality; 5-year patient and graft survival was 35/50 (70% in group 1 [human leukocyte antigen +ve]), 7/9 (77.8%), and 28/41 in group 2 (68.3%) (human leukocyte antigen -ve). Conclusions: Positive human leukocyte antigen typing before live-donor liver transplant has no effect on the incidence of postoperative complications, rejection episodes, and patient or graft survival. Recipients with positive human leukocyte antigen typing may have increased risk of hepatitis C virus-recurrence after live-donor liver transplant.
dc.identifier.citationExperimental and Clinical Transplantation, Cilt, 10, Sayı, 2, 2012 ss. 136-140en
dc.identifier.eissn2146-8427en
dc.identifier.issn1304-0855
dc.identifier.issue2en
dc.identifier.urihttps://hdl.handle.net/11727/14827
dc.identifier.volume10en
dc.language.isoen
dc.publisherBaşkent Üniversitesi
dc.sourceExperimental and Clinical Transplantationen
dc.subjectHLA
dc.subjectLiver transplantatio
dc.subjectOutcome
dc.titleHLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
136.pdf
Size:
192.44 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: